Table 1.
Ongoing clinical trials for ROS1-rearranged NSCLC.
| Study drug | Company | Phase | Target kinases | Primary outcome | Study location | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|---|
| Crizotinib | Pfizer | II | ROS1, ALK, MET | ORR | France | NCT02034981 |
| Crizotinib | Pfizer | II | ROS1 | ORR | Europe | NCT02183870 |
| Crizotinib | Pfizer | II | ROS1, ALK, MET | ORR | UK | NCT02664935 |
| Crizotinib | Pfizer | II | ROS1, MET | ORR | Italy | NCT02499614 |
| Ceritinib | Novartis | II | ROS1 | ORR | ROK | NCT01964157 |
| Ceritinib | Novartis | II | ROS1, ALK | ORR | China | NCT02276027 |
| Lorlatinib | Pfizer | II | ROS1, ALK | ORR | Global | NCT01970865* |
| Lorlatinib | Pfizer | II | ROS1, ALK | Intracranial DCR | USA | NCT02927340 |
| Entrectinib | Ignyta | II | ROS1, ALK, TRK A/B/C | ORR | Global | NCT02568267 |
| Cabozantinib | Exelixis | II | ROS1, TRK A/B/C, RET, MET, AXL | ORR | USA | NCT01639508 |
| DS-6051b | Daiichi Sankyo | I | ROS1, TRK A/B/C | Toxicity profile, ORR | USA | NCT02279433 |
| DS-6051b | Daiichi Sankyo | I | ROS1, TRK A/B/C | Toxicity profile | Japan | NCT02675491 |
| TPX-0005 | TP Therapeutics | I | ROS1, ALK, TRK A/B/C | Toxicity profile, ORR | USA, ROK | NCT03093116 |
*
This trial is now closed to accrual for ROS1 patients.
Note: While there are currently no open clinical trials of brigatinib in ROS1-rearranged NSCLC, brigatinib is also known to have anti-ROS1 activity.
Abbreviations: NSCLC, non-small cell lung cancer; ORR, objective response rate; DCR, disease control rate; UK, United Kingdom; USA, United States of America; ROK, Republic of Korea.